Using frozen stool from healthy, unrelated donors was safe and effective in treating patients with serious, relapsing diarrhea caused by Clostridium difficile, according to a new pilot study published in Clinical Infectious Diseases and available online.
Known as fecal microbiota transplantation, the treatment was equally effective whether given via a colonoscope or a nasogastric tube. The findings suggest approaches that may make this promising treatment more readily available to patients.
A growing concern, C. difficile causes 250,000 infections requiring hospitalization and 14,000 deaths in the U.S. each year, according to the Centers for Disease Control and Prevention. Infection incidence has tripled in the last 15 years and is responsible for at least $1 billion in excess U.S. medical costs per year.
In an initial feasibility study, Ilan Youngster, MD, and colleagues at Massachusetts General Hospital (MGH) treated 20 patients suffering from repeated episodes of C. difficile infection with fecal microbiota transplantation, which helps restore the normal balance of bacteria in the affected person's gut. Fourteen of the patients were cured after one administration of donated stool. Of the remaining six patients, five received a second administration, and four were cured, for an overall cure rate of 90 percent.
Unlike previous studies, which used fresh stools from donors, the team at MGH worked with frozen material from unrelated donors who had been recruited and screened well ahead of time, a "banking" approach that may help overcome current treatment barriers.
"Establishing a repository of prescreened frozen donor stools could make this treatment available for a wider population," the authors noted, as donor recruitment and screening can be lengthy and costly. The Food and Drug Administration is currently determining how it will regulate fecal microbiota transplantation, including what steps clinicians must take to provide it to patients.
For their first administration, patients were assigned to one of two delivery methods, using either a colonoscope or a nasogastric tube, inserted in the nose and down into the stomach. Both appeared to be equally effective. Patients who required a second infusion were allowed to choose between the two methods, and all five chose the nasogastric tube.
"Colonoscopy is a significant procedure requiring sedation," said Elizabeth L. Hohmann, MD, of MGH and a study co-author, while the nasogastric tube method "is an outpatient office procedure."
The study's findings suggest the latter would be a "cost-effective, upper gastrointestinal route" for transplantation, Dr. Hohmann said, particularly for elderly or debilitated patients who may not tolerate a colonoscopy. The researchers are now studying placing the donated material into a frozen capsule, which patients would take orally.
1. A significant cause of life-threatening diarrhea, Clostridium difficile is responsible for 250,000 infections requiring hospitalization and 14,000 deaths in the U.S. each year. Relapsing infections are a serious problem.
2. This initial feasibility study found that using frozen stool from healthy, unrelated donors was safe and effective in treating a small group of patients with relapsing C. difficile infections, with an overall cure rate of 90 percent.
3. The treatment, known as fecal microbiota transplantation, appeared to be equally effective whether given via a colonoscope or a nasogastric tube.
Editor's note: The authors' affiliations, acknowledgments, and disclosures of financial support and potential conflicts of interests are available in the article, which is embargoed until 12:01 a.m. EDT on Thursday, April 24. To obtain an embargoed copy of the article, please contact Jerica Pitts at email@example.com or 312-558-1770.
Clinical Infectious Diseases is a leading journal in the field of infectious disease with a broad international readership. The journal publishes articles on a variety of subjects of interest to practitioners and researchers. Topics range from clinical descriptions of infections, public health, microbiology, and immunology to the prevention of infection, the evaluation of current and novel treatments, and the promotion of optimal practices for diagnosis and treatment. The journal publishes original research, editorial commentaries, review articles, and practice guidelines and is among the most highly cited journals in the field of infectious diseases. Clinical Infectious Diseases is an official publication of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing nearly 10,000 physicians and scientists who specialize in infectious diseases. For more information, visit http://www.idsociety.org. Follow IDSA on Facebook and Twitter.
Jerica Pitts | Eurek Alert!
ARTORG and Inselspital develop artificial pancreas
26.11.2015 | Universitätsspital Bern
Laboratory study: Scientists from Cologne explore a new approach to prevent newborn epilepsies
24.11.2015 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Planet Earth experienced a global climate shift in the late 1980s on an unprecedented scale, fuelled by anthropogenic warming and a volcanic eruption, according to new research published this week.
Scientists say that a major step change, or ‘regime shift’, in the Earth’s biophysical systems, from the upper atmosphere to the depths of the ocean and from...
The Fraunhofer Institute for Solar Energy Systems ISE has installed 70 photovoltaic modules on the outer façade of one of its lab buildings. The modules were...
Nerve cells cover their high energy demand with glucose and lactate. Scientists of the University of Zurich now provide new support for this. They show for the first time in the intact mouse brain evidence for an exchange of lactate between different brain cells. With this study they were able to confirm a 20-year old hypothesis.
In comparison to other organs, the human brain has the highest energy requirements. The supply of energy for nerve cells and the particular role of lactic acid...
In laser material processing, the simulation of processes has made great strides over the past few years. Today, the software can predict relatively well what will happen on the workpiece. Unfortunately, it is also highly complex and requires a lot of computing time. Thanks to clever simplification, experts from Fraunhofer ILT are now able to offer the first-ever simulation software that calculates processes in real time and also runs on tablet computers and smartphones. The fast software enables users to do without expensive experiments and to find optimum process parameters even more effectively.
Before now, the reliable simulation of laser processes was a job for experts. Armed with sophisticated software packages and after many hours on computer...
Researchers at Heidelberg University have devised a new way to study the phenomenon of magnetism. Using ultracold atoms at near absolute zero, they prepared a...
25.11.2015 | Event News
17.11.2015 | Event News
21.10.2015 | Event News
26.11.2015 | Ecology, The Environment and Conservation
26.11.2015 | Materials Sciences
26.11.2015 | Earth Sciences